PureTech Presents Phase 1 Data for LYT-100 at the European Respiratory Society International Congress 2021
23 August 2021 - 9:00PM
Business Wire
LYT-100 was well-tolerated when given
twice-daily over multiple ascending doses with no maximum tolerated
dose observed
Results demonstrated dose-proportional PK
profile and a modest food effect
LYT-100 is currently being evaluated in two
Phase 2 trials in patients with Long COVID respiratory
complications or breast cancer-related, upper limb secondary
lymphedema, and planning is underway to potentially evaluate
LYT-100 in IPF
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases, today announced the
presentation of the Phase 1 multiple ascending dose and food effect
study of LYT-100 at the virtual European Respiratory Society
International Congress. LYT-100 is the lead therapeutic candidate
from within PureTech’s Wholly Owned Pipeline, and it is being
advanced for the potential treatment of conditions involving
inflammation and fibrosis and disorders of lymphatic flow.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210823005064/en/
PureTech Health today announced the
presentation of the Phase 1 multiple ascending dose and food effect
study of LYT-100 at the virtual European Respiratory Society
International Congress. LYT-100 is the lead therapeutic candidate
from within PureTech’s Wholly Owned Pipeline, and it is being
advanced for the potential treatment of conditions involving
inflammation and fibrosis and disorders of lymphatic flow. (Photo:
Business Wire)
“These data further support the favorable tolerability profile
of LYT-100 and have helped inform both our ongoing Phase 2 trials
as well as potential future trials in additional indications,
including idiopathic pulmonary fibrosis,” said Michael Chen, PhD,
Head of Innovation at PureTech. “LYT-100 is a deuterated form of
pirfenidone, which retains the beneficial pharmacology of
pirfenidone and also appears to have a favorable tolerability
profile based on the preclinical and clinical data generated thus
far. We believe this molecule has the potential to overcome the GI
adverse events associated with the current standards of care and
become the frontline treatment for patients with interstitial lung
disease.”
Multiple ascending dose and food effect study results The
Phase 1 multiple ascending dose food and effect study was a
randomized, double-blind, placebo-controlled study of LYT-100 in
healthy volunteers in both fed and fasting states. Plasma
concentrations of LYT-100 and its metabolites were measured to
determine pharmacokinetic (PK) parameters.
Topline results from the Phase 1 study were first announced in
November 2020. The expanded analysis details the safety,
tolerability and favorable PK profile of LYT-100 at doses from
100mg to 1000mg in both fed and fasting healthy volunteers and
supports the potential for twice-daily dosing in future
studies.
A dose-proportional PK profile was observed with LYT-100
throughout the range of doses studied. In the single ascending food
effect cohort, exposure was slightly lower in the fed condition.
The ratios of exposure during fed conditions were approximately 20%
to 25% less than exposure during fasting.
Given that the maximum tolerated dose for LYT-100 was not
determined in this study, PureTech initiated a second multiple
ascending dose study earlier this year to evaluate higher doses of
the drug in healthy volunteers.
About LYT-100 LYT-100 is PureTech’s most advanced
therapeutic candidate from within its Wholly Owned Pipeline. A
deuterated form of pirfenidone, an approved anti-inflammatory and
anti-fibrotic drug, LYT-100 is being advanced for the potential
treatment of conditions involving inflammation and fibrosis,
including lung disease (e.g., IPF and potentially other PF-ILDs and
Long COVID respiratory complications and related sequelae), and
disorders of lymphatic flow, such as lymphedema. PureTech completed
a Phase 1 multiple ascending dose and food effect study evaluating
LYT-100 in healthy volunteers and found it to be well-tolerated at
all doses tested. In the fourth quarter of 2020, PureTech initiated
a Phase 2 trial evaluating LYT-100 as a potential treatment for
Long COVID respiratory complications and related sequalae and a
Phase 2a proof-of-concept study evaluating LYT-100 in patients with
breast cancer-related, upper limb secondary lymphedema. PureTech
has also initiated three additional Phase 1 clinical trials to
explore further the PK, dosing and tolerability of LYT-100 in
healthy volunteers. Results from these trials are anticipated in
the fourth quarter of 2021 and are expected to provide additional
supportive data that may inform the clinical development of LYT-100
across indications, including IPF and other PF-ILDs.
About PureTech Health PureTech is a clinical-stage
biotherapeutics company dedicated to discovering, developing and
commercializing highly differentiated medicines for devastating
diseases, including inflammatory, fibrotic and immunological
conditions, intractable cancers, lymphatic and gastrointestinal
diseases and neurological and neuropsychological disorders, among
others. The Company has created a broad and deep pipeline through
the expertise of its experienced research and development team and
its extensive network of scientists, clinicians and industry
leaders. This pipeline, which is being advanced both internally and
through PureTech's Founded Entities, is comprised of 26
therapeutics and therapeutic candidates, including two that have
received FDA clearance and European marketing authorization, as of
the date of PureTech's most recently filed Annual Report on Form
20-F. All of the underlying programs and platforms that resulted in
this pipeline of therapeutic candidates were initially identified
or discovered and then advanced by the PureTech team through key
validation points based on the Company's unique insights into the
biology of the brain, immune and gut, or BIG, systems and the
interface between those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements This
press release contains statements that are or may be
forward-looking statements, including statements that relate to our
product candidates and approach towards addressing major diseases,
future prospects, developments, and strategies. The forward-looking
statements are based on current expectations and are subject to
known and unknown risks and uncertainties that could cause actual
results, performance and achievements to differ materially from
current expectations, including, but not limited to, our
expectations regarding the potential therapeutic benefit of LYT-100
in patients with conditions involving inflammation and fibrosis and
disorders of lymphatic flow, expectations regarding data from our
current Phase 1 and 2 trials of LYT-200 and their potential to
provide supportive data for further development and those risks and
uncertainties described in the risk factors included in the
regulatory filings for PureTech Health plc. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company
nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210823005064/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com
U.S. Media Nichole Sarkis +1 774 278 8273
nichole@tenbridgecommunications.com
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024